News
Upgraded Relay Therapeutics to a buy after valuation decline. Read more on RLAY's pipeline progress, financial health, and ...
Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...
New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...
5d
Stocktwits on MSNThis Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s WhyCelcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination ...
SAN ANTONIO — Futibatinib plus fulvestrant exhibited antitumor activity among certain patients with locally advanced or metastatic breast cancer with fibroblast growth factor receptor 1 ...
Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...
PATIENTS AND METHODS: Patients (n = 451) with advanced breast cancer were randomized to receive fulvestrant 250 mg as a once-monthly (one × 5 mL) intramuscular injection or an oral dose of anastrozole ...
The patients were randomly assigned to receive alisertib monotherapy (n=46) or alisertib plus fulvestrant (n=45). Prior chemotherapy for metastatic disease was more common in the combination arm ...
Fulvestrant has demonstrated efficacy in the treatment of postmenopausal women with advanced, hormone-sensitive breast cancer, with data indicating that fulvestrant exhibits this activity in both ...
Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results